The U.S. Food and Drug Administration (FDA) will review Amneal Pharmaceuticals’ application for IPX203, its extended-release carbidopa/levodopa (CD/LD) tablet for Parkinson’s disease. Results from the Phase 3 RISE-PD clinical trial (NCT03670953) showed IPX203 can control Parkinson’s symptoms safely and effectively for longer periods with less frequent dosing,…
The Parkinson’s Foundation is accepting applications for its 2023 community grants, awarding a total of $1 million in support of local health, wellness, and educational programs helping to address the unmet needs of Parkinson’s disease communities. Awards range from $10,000 to $25,000, and the funding period runs from July…
Transposable elements, a common feature in the so-called “dark genome,” are associated with clinical differences in how Parkinson’s disease progresses among different people, a new study indicates. “Our main finding is that the presence or absence of [transposable elements] changes progression trajectory of [Parkinson’s], and we provided clinical, imaging,…
Dry eye disease (DED) is common in people with Parkinson’s disease, with more than 60% of patients reporting that they experience its symptoms, according to a recent meta-analysis. Clinical signs of this disease, which include a lower rate of blinking, reduced corneal thickness, a lesser tear secretion, and a…
MindMaze is partnering with Mount Sinai Health System in New York to accelerate the access of people with neurological diseases to a pioneer digital neurotherapeutic program to improve patients’ motor and cognitive functions. The program aims to provide high-dose and high-intensity training to improve the brain’s ability…
Treatment with simvastatin, a medication used to lower cholesterol levels, did not slow the progression of Parkinson’s disease over a two-year period, according to published data from a Phase 2 trial. Overall, the data provide “no evidence to support proceeding to a phase 3 trial,” the researchers wrote, noting…
Aggression aimed at caregivers in Parkinson’s disease and related disorders is associated with patients’ grief in coping with disease progression and related losses, a new study suggests. Fluctuations in cognition also play a role, researchers say. But these behavioral disturbances have serious consequences for caregivers, according to investigators, who…
NKGen Biotech is partnering with the Parkinson’s Foundation to help accelerate clinical research on its natural killer cell therapy, SNK01, for advanced Parkinson’s disease. “We are very impressed with the Parkinson’s Foundation’s holistic approach towards improving patient care and supporting cutting-edge research,” Paul Y. Song, MD, NKGen…
Treatment with DopaFuse, a continuous oral levodopa-carbidopa delivery system being developed by SynAgile, was safe and lessened motor complications in people with Parkinson’s disease, according to results from a Phase 2 clinical trial. “These results suggest that the DopaFuse [levodopa-carbidopa] delivery system can provide a safe, non-invasive…
A gene therapy designed to track down and keep overactive brain cells in check was able to lower the number of seizures in a mouse study of epilepsy. This therapy is also notable in sparing healthy brain tissue by switching itself off after its work is done. Should early work…
Get regular updates to your inbox.
